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Summary Serial image guided 31P magnetic resonance spectroscopy (MRS) studies were performed in eight
patients with non-Hodgkin's lymphoma to determine the changes in phosphorus metabolites that occur in vivo
in response to chemotherapy. Pre-treatment spectral characteristics were different in high and low grade
lymphoma. A larger inorganic phosphate (Pi) peak was seen in high grade NHL relative to phospho-
monoesters (PME) or P adenosine triphosphate (PATP), producing significant differences in the PME/Pi and
Pi/PATP metabolite ratios, and probably reflecting a larger hypoxic cell fraction within the high grade
lymphomas. Consistent metabolite changes were seen with treatment, and before reductions in tumour bulk
had occurred. Alterations in tumour energetics with changes in Pi and PATP, and increases in phospholipid
turnover reflected as an increase in the phosphodiester (PDE) resonance were detected. Changes were seen
between days 10 and 27 in low grade lymphoma treated with oral alkylating therapy and between days I and 5
in lymphoma treated with intensive combination chemotherapy. Increases in the PDE/PATP metabolite ratio
may be an early indicator of response to chemotherapy in human tumours. These studies illustrate the
feasibility and clinical potential of image guided 31P MRS as a means of assessing response to therapy.
Magnetic resonance spectroscopy provides a totally non-
invasive means of investigating the chemistry of human tis-
sues and organs. 31P MRS allows the metabolites involved in
bioenergetic pathways and phospholipid turnover to be
monitored, as well as providing a non-invasive means of
measuring tissue pH.
High resolution MRS studies on tumour cell lines, and
tumours implanted in rodents have shown the potential of
31p MRS in cancer (Evanochko et al., 1984; Sostman et al.,
1984; Maris & Chance, 1986; Daly & Cohen, 1989). It is only
relatively recently, however, with the advent of high field (1.5
Tesla), whole body, combined imaging and spectroscopy
systems, that knowledge gained from these studies could be
applied to the study of human tumours in vivo.
The ability to monitor biochemical changes in human
tumours non-invasively raises the possibility of the early
prediction of treatment response, and monitoring for
development of drug resistance (Cohen et al., 1986). In vivo
MRS studies assessing tumour response to therapy are
limited; the histological types of tumour studied have been
very varied, and the use of different MRS data acquisition
and processing techniques has made comparisons between
studies difficult. These studies have recently been reviewed
(Daly & Cohen, 1989; Bottomly, 1989; Steen, 1989).
We have used an image guided slice selective MRS
localisation technique to obtain well resolved 31p spectra
serially from eight patients with non-Hodgkin's lymphoma
(NHL). The aim of this preliminary study being three-fold; to
identify the pre-treatment phosphorus characteristics of low
and high grade NHL; to establish by serial studies in the
early period after the commencement of chemotherapy the
31p MRS characteristics that are associated with, or possibly
predictive of a response to therapy; and finally to identify the
time period in which these changes occur in relation to
chemotherapy.
Patients and methods
Eight patients with newly diagnosed NHL were studied.
Local ethical committee approval was obtained and all
patients gave written consent. MRS examinations were per-
formed before starting chemotherapy and serially at various
times after commencing treatment.
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Patients were staged by conventional techniques and histo-
logical diagnosis made by examination of bone marrow
biopsy, lymph node biopsy and/or trucut biopsy of the
abdominal mass. Lymphomas were classified according to the
working formulation for the classification of Non-Hodgkin's
lymphomas. All patients had marked splenomegaly or bulky
disease in the lower abdomen. In six cases spectroscopic
studies were of splenic lymphoma and in two cases of
superficial abdominal lymphoma. Details of the
chemotherapy received by each patient, the site studied, and
timing of MR examinations in relation to therapy are sum-
marised in Table I.
MR examinations were performed on a 1.5 Tesla General
Electric (GE) Signa system. MRS studies were performed
with 8 cm (seven patients) or 11 cm (one patient) home built
surface coils tuned to 25.86 MHz. A one-dimensional
chemical shift imaging technique (1D-CSI) (one spatial and
one chemical shift dimension), was used to acquire 31P spec-
tra from tomographically localised 1 cm thick slices of tissue.
Before spectroscopy examinations multi-slice gradient echo
imaging was performed to confirm surface coil positioning,
to assess tumour size, and to confirm that tumour dimensions
exceeded the size of the coil being used. The surface coils
contained phantoms visible on MR images enabling the posi-
tion of the surface coils over the tumours to be carefully
controlled. All phosphorus studies were performed with con-
sistent acquisition parameters, a repetition time of 500 ms
and 12 or 16 averages being used for all studies. Details of
the technique have been reported previously (Glazer et al.,
1989; Smith et al., 1990). Combined imaging and spectro-
scopy studies took approximately one hour to perform.
Data processing was performed on a GE-satellite data
station. Metabolite peak areas were measured using an
interactive computer curve fitting routine (GENCAP), assum-
ing 100% Lorentzian line shapes. A baseline correction was
performed in the wings of the spectrum to facilitate use of
the GENCAP routine. All quantitative data were derived
from the spectrum obtained 4cm from the surface coil, as
this slice always encompassed the tumours. Peak areas were
expressed as a percentage of total phosphorus, and relative
metabolite ratios calculated. Changes in peak areas and
metabolite ratios with treatment were expressed as a percent
change relative to the pre-treatment study.
As phosphocreatine was absent from many of the spectra,
aATP was assigned a chemical shift of - 7.5 p.p.m. and used
as a reference to measure pH (Naruse et al., 1985; Ng et al.
1989b). pH was obtained from the chemical shift of Pi
relative to PCr using the following calibration curve:
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Table I Patient characteristics
Timing of
Patient WF Stage of Site MR studies Treatment
no. Age Sex classification disease studied (days) received
1 66 F C IV Spleen - 1,6,11,20,41 Chlorambucil 0.1 mgkg-' days 1-22
then 2 out of every 4 weeks
2 78 F A IV Spleen - 1,14,27,42 Chlorambucil 0.1 mgkg-' daily
3 65 F C IV Spleen - 1,11,18,25,35 Prednisolone 40mg days 1-7
Chlorambucil 0.1 mgkg-' from day 12
4 32 F C IV Spleen - 3,2,3,6,10,15, 14mg mitozantrone day 1,
30,37,55 500mg cyclophosphamide day I
Chlorambucil 0.1 mgkg-' from day 2
5 58 M C IV Lower abdomen - 2,5,10,20 CHOPa
6 78 M H IV Lower abdomen - 1,3,7,29 CHOPS
7 56 M J IV Spleen - 1,28,90 PCOMMBb
8 56 F H IV Spleen - 1,1,2,4,7,10,14,17 PCCOMBb
WF=international working formulation for the classification of lymphomas. aCyclophosphamide 750mgm2 i.v. day 1, adriamycin
50mgm-2 i.v. day 1, vincristine 1.4mgm2, prednisolone 60mg orally days 1-5. bSee Philips (1987).
pH = 6.75 + log (a - 3.27)/(5.69 - a)
where a is the chemical shift in parts per million between the
Pi and PCr signals (Taylor et al., 1983).
The significance of differences in pre-treatment metabolite
ratios between high and low grade NHL was assessed using
the Mann-Whitney U test.
Results
Pre-treatment studies
Figure 1 shows an axial gradient echo image of the lower
abdomen in a patient with low grade NHL. The position of
the surface coil and the slice 4 cm off the coil from which the
spectrum used for metabolite estimation was obtained is
shown. Figure 2 shows the spectra obtained with the ID-CSI
technique from this patient. Note the spectrum from the
superficial slice immediately adjacent to the surface coil is
consistent with that from muscle in the anterior abdominal
Figure I Axial gradient echo MR image through the abdomen
of patient 5 showing bulky abdominal lymphoma. The position
of the surface coil and the slice 4 cm from the surface coil from
which the spectrum used for metabolite estimation was obtained
is shown.
wall (prominent phosphocreatine (PCr) and three resonances
of adenosine triphosphate (ATP)). The high energy substrate
PCr is absent from the spectra localised to the lymphoma
(slices at 3, 4 and 5 cm off the surface coil), and a very
prominent phosphomonoester (PME) peak in relation to
PATP or inorganic phosphate (Pi) is present. Well resolved
spectra with acceptable signal to noise were obtained in all
patients.
Pre-treatment metabolite ratios are shown in Table II. Low
and high grade lymphomas could be distinguished on the
basis of spectral characteristics with the high grade tumours
having a larger Pi peak relative to PME or PATP (Figure 3).
This produced significant differences in the PME/Pi
(P = 0.018) and Pi/PATP (P = 0.036) metabolite ratios
between the two groups. The PME/Pi ratio produced the best
separation between low and high grade lymphomas.
Post-treatment studies
All patients had serial studies performed after commencing
chemotherapy. Changes in tumour metabolites were seen
prior to reductions in tumour size in all patients except
patient 7, whose first follow-up study at day 28 was after a
reduction in tumour size had occurred.
In low grade lymphoma treated with oral alkylating agents
(patients 1-4) very consistent metabolite changes were seen
after therapy was commenced. These changes consisted of a
relative increase in Pi peak area and decrease in PATP,
followed by increases in the phosphodiesters (PDE). Alter-
ations in tumour metabolism were detected by 31P MRS
between days 10 and 27 of commencing therapy in patients
with low grade NHL. Figure 4 illustrates the phosphorus
metabolite changes seen in patient 1 after starting
chemotherapy, and their relationship to changes in tumour
size.
Patient 5 with bulky abdominal disease treated with more
intensive combination chemotherapy (CHOP) showed a
similar pattern of change in metabolites, however they were
detected much earlier by day 5.
The metabolic changes seen in high grade abdominal lym-
phoma (patient 6) treated with intravenous combination
chemotherapy are illustrated in Figure 5. By day 3 marked
Table II Pre-treatment 31P metabolite ratios and pH data
Pi/pATP- PME/PATP PDE/IpATP PME/Pib PDE/Pi pH
Patient 1 0.34 1.34 0.95 4.00 2.83 7.23
Patient 2 0.28 0.98 0.27 3.46 0.94 7.39
Patient 3 0.18 1.38 0.37 7.70 2.09 7.39
Patient 4 0.29 1.38 0.92 4.70 3.13 7.31
Patient 5 0.27 2.01 2.10 7.51 7.86 7.16
Patient 6 0.79 0.69 1.12 0.87 1.42 6.97
Patient 7 1.87 1.86 1.14 0.99 0.61 7.24
Patient 8 0.57 1.08 0.98 1.85 1.70 7.61
ap =0.036, bp = 0.018 (Mann-Whitney U test); significance of differences between pre-treatment metabolite ratios of
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Figure 2 Set of pre-treatment phosphorus spectra of low grade
NHL obtained with the ID-CSI technique from patient 5. 10 Hz
line broadening has been applied. Peak assignments as shown
(PME = phosphomonoesters; Pi = inorganic phosphate; PDE
= phosphodiesters; PCr = phosphocreatine; a, , y - ATP = a,
- adenosine trophosphate). Distance of each 1 cm slice of
tissue off the surface coil from which spectra were obtained is
also shown.
changes in Pi and PDE were already detectable, and were
subsequently followed by a large reduction in tumour volume
by day 7. Immediately before the next course of therapy
relative metabolite levels had returned to near pre-treatment
levels.
In patient 8 alterations in metabolites within 24 h of com-
mencing therapy were detected with a relative increase in
PDE and a decrease in PATP. This patient was studied very
closely through the first three weeks of therapy with a multi-
agent chemotherapeutic regime, PCOMMB (Philips, 1987).
In this regime pairs of chemotherapeutic agents are given at
weekly intervals and these studies allowed the response to
each weekly drug combination to be assessed. A response to
each drug combination was seen with a maximal rise in the
PDE/PATP metabolite ratio by the second or third day
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Figure 3 Pre-treatment spectra from patients with (a) high grade
NHL and (b) low grade NHL obtained 4cm from the surface
coil. Peak assignments as in Figure 2.
following each weekly treatment (Figure 6). A similar but less
marked pattern ofchange was also seen in the Pi/PATP ratio.
Immediately before the next treatment,-metabolite levels were
approaching pre-treatment baseline values.
Of the metabolite ratios examined the most consistent
alterations with treatment were observed in the PDE/PATP
ratio. All tumours showed marked increases in the PDE/
PATP metabolite ratio (51-266%) with therapy. These488 S.R. SMITH et al.
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Figure 4 Metabolite changes in low grade splenic lymphoma
(patient 1), treated with oral alkylating agents. Results are shown
as per cent change in metabolites in relation to pre-treatment
value against days after commencing therapy. Timing of treat-
ment, per cent reductions in tumour size, and alterations in
tumour pH are also shown. -0- PME, -A Pi, -A- PDE, o-
PATP.
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Figure 5 Metabolic changes of high grade abdominal lymphoma
treated with combination chemotherapy (patient 6). Results are
expressed as in Figure 4. -0- PME, -A- Pi, -A PDE, o-
PATP.
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Figure 6 Serial studies in patient 8 showing the changes in the
metabolite ratios PDE/PATP, and Pi/PATP over the first three
weeks of treatment and their relation to the timing of therapy.
Week I = mitozantrone 1Omg m2 i.v. and cyclophosphamide
350 mg m ' i.v.; week 2 = vincristine 1.4 mg m-2 i.v., methotrex-
ate 400 mgm2 over 4 h i.v.; week 3 as week 1; prednisolone
75 mg p.o. continuously. -A - Pi/PATP, -0- PDE/PATP.
changes were seen before tumour shrinkage in all patients
except patient 7. The maximum changes in this ratio and
their relation to time after commencing chemotherapy are
summarised in Figure 7.
Pre-treatment pH values are shown in Table II. pH values
were normal or alkaline in low grade lymphoma (range
7.16-7.39 pH units). The range of pH values was greater in
high grade NHL (6.99-7.61 pH units). No set pattern of pH
change was seen with treatment, but pH remained very
alkaline in some cases even in the presence of increased Pi
(Figure 4).
Discussion
The potential of MRS to assess treatment response in
tumours has been well documented in animal models
(Evanochko et al., 1984; Sostman et al., 1984; Maris &
Chance, 1986; Daly & Cohen, 1989; Steen et al., 1989).
However, due to difficulties in performing in vivo MRS (low
MR sensitivity of phosphorus containing compounds, low
signal-to-noise ratio of in vivo spectra, poor spatial localisa-
tion of the MR signal, long examination time and patient
compliance), only a few studies have been reported assessing
early treatment response in human tumours (Ng et al., 1987,
1989a; Semmler et al., 1988a, b). These studies all used whole
volume MRS localisation techniques therefore the spectra
acquired from some of the tumours would have been con-
taminated with signal from surrounding non-tumour tissue.
Phase encoding spectroscopic techniques have been used to
assess treatment response in two patients with B cell non-
Hodgkin's lymphoma of bone (Bryant et al., 1988).
We have previously shown that the lD-CSI technique is a
reproducible method of obtaining localised in vivo 31P spectra
from human organs (Glazer et al., 1989; Smith et al., 1990).
It is important to note, however, that the metabolite ratios
reported are relative ratios and are not absolute metabolite
concentrations.
As lymphomas generally respond well to chemotherapy,
and frequently present with very bulky superficial disease
they are suitable to be studied by currently available MRS
localisation techniques. This is the largest reported series of
patients with similar tumour types studied with an image
guided spectroscopic localisation technique to assess the 31P
MRS characteristics that are associated with a response to
chemotherapy.
Very reproducible spectral patterns were seen in both
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Figure 7 The maximum per cent change in the PDE/PATP
metabolite ratio in relation to time after commencing therapy is
shown for each patient. Patients numbered as in Table I
(patient 7 not shown). --- Low grade NHL, -0- high grade
NHL.31P MRS AND NON-HODGKIN'S LYMPHOMA 489
groups of lymphoma. The major pre-treatment difference in
31P characteristics between high and low grade lymphomas
related to tumour bioenergetics. The Pi peak area was larger
in relation to PME or PATP in high grade lymphoma. This
presumably represents a larger hypoxic cell fraction in high
grade lymphoma and may be due to out growth of tumour
blood supply.
One may have expected the pH measured in some of these
tumours to be more acidic due to lactate production but an
alkaline pH is consistent with pH measurements reported for
other human tumours (Ng et al., 1989b; Oberhaensli et al.,
1986). Mechanisms proposed for the production of this
alkaline tumour pH include raised intracellular pH in rela-
tion to cell growth and activation of Na+/H+ exchange
(Schuldiner & Rozengurt, 1982; Hesketh et al., 1985). The
variation in pH in these lymphomas may reflect aspects of
tumour heterogeneity, or have been related to limits of data
resolution and the use of xATP as a reference from which to
measure pH (Smith et al., 1990).
Prominent PME resonances were seen in all tumours. The
major constituents of the PME peak, phosphocholine and
phosphoethanolamaine represent the anabolic pathway of
phospholipid turnover and may relate to proliferation rates
of tumours (Daly et al., 1987). However, no clear relation-
ship between relative PME peak area and grade of malig-
nancy was seen. Further studies directed at the documenta-
tion ofabsolute concentrations ofphosphomonoesters will be
needed to clarify this issue.
31P metabolite changes were observed before any reduction
in tumour size had occurred. As the tumours studied were
large and greatly exceeded the size of the surface coils used,
we were confident that metabolite changes detected before
reductions in tumour size reflected changes occurring in these
tumours and were not due to partial volume effects.
In low grade NHL the metabolite changes observed with
treatment consisted of increases in Pi and an associated fall
in PATP, consistent with the development of an increasing
proportion of hypoxic or dying cells within the tumour bulk.
These changes were followed by relative increases in PDE.
Glycerophosphorylcholine and glycerophosphorylethanol-
amine are the major constituents of the PDE peak and repre-
sent the catabolic side of phospholipid turnover (Daly et al.,
1987). Increased flux through this pathway as suggested by
relative increases in PDE peak area may therefore represent
mobilisation of cell membrane components associated with
cell death.
In tumours with high growth fractions the response to
chemotherapy can be rapid. In high grade lymphoma
metabolite changes were detected by days 1 and 3 of
chemotherapy (patients 8 and 6). Although similar changes in
PDE and PATP were detected in high grade NHL as seen in
low grade tumours, alterations in Pi in high grade NHL were
more variable. This may relate to the timing of 31P studies
after starting treatment, studies performed on day 1 or 2 in
patient 6 may have detected earlier changes in tumour
bioenergetics. The major difference in metabolic response to
chemotherapy between high and low grade lymphoma was
the time changes in the PDE/,BATP ratio occurred in relation
to the intensity of treatment given. In patients with low grade
tumours given oral alkylating agents 31P MRS changes were
seen between days 10 and 27 of starting therapy while in
tumours given intensive combination chemotherapy changes
were seen between days I and 5.
The serial studies in patient 8 allowed the response to
weekly administrations of different chemotherapeutic drug
combinations to be assessed, potentially allowing the more
critical documentation of the efficacy of different agents in
timed multiagent chemotherapy regimes.
All tumours responded well to their initial treatment
schedules as measured by reduction of tumour bulk. The
most consistent metabolic change seen in all tumours was an
increase in the PDE/,BATP ratio. Some tumours showed in-
creases in the Pi/PATP ratio with treatment, although
alterations in this ratio have been reported in untreated
growth in animal tumours (Wehrle & Glickson, 1986) and in
a human rhabdomyosarcoma unresponsive to therapy
(Griffiths et al., 1983). The PDE/PATP ratio may therefore
be a more useful indicator ofearly response to chemotherapy
in lymphomas, incorporating the metabolic changes seen in
tumour bioenergetics with those of phospholipid turnover.
Increases in the PDE/,ATP ratio have been reported as
being associated with a good response to therapy in both
subcutaneously implanted tumours in animals (Lutz et al.,
1989) and in human tumours (Semmler et al., 1988b). In vivo
MRS does not adequately resolve the individual resonances
within the PME and PDE peaks but it has been suggested
from high resolution tumour extract studies that it is an
increase in the glycerophosphorylcholine component that is
responsible for the relative increase in the PDE peak (Lutz &
Wehrle, 1989).
In contrast to some recent reports we did not see any
alterations in PME in the early studies after commencing
therapy (Glaholm et al., 1989; Ng et al., 1989a). In later
studies (approximately 5 months after initially starting treat-
ment) in patients 1 and 4, marked decreases in PME were
seen but these probably reflected alterations in the cell
populations of the tumours as large reductions in tumour
volume had by then occurred.
In this study, therefore, a reproducible slice selective MRS
protocol was used to study a homogeneous group of patients.
Very consistent metabolite changes were seen in these
tumours after commencing chemotherapy. The PDE/PATP
metabolite ratio may be a good metabolic indicator of early
response to chemotherapy in lymphomas. These studies raise
the possibility of performing specifically timed 31p MRS
studies during treatment to assess the early efficacy of a
treatment protocol in individual patients. The lack of appro-
priate metabolic change possibly being an indication for
alteration in treatment at an earlier time than conventional
practice currently allows. Obviously more detailed studies
need to be performed in well defined patient groups before
the role of 31P MRS in clinical oncology and therapeutics can
be fully established, but these preliminary studies illustrate
the feasibility and clinical potential of phosphorus MRS.
This work was supported by a grant from the North West Cancer
Research Fund. We are grateful for the patients' co-operation during
the course of these studies.
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